Clinical Omics and Mass Spectrometry

Listicle

Last Updated: April 13, 2022

Written by

Clinical Omics and Mass Spectrometry content piece image

Results of large-scale omics studies have led to significant advances in the biomedical understanding of a variety of biological phenomena, including the development and progression of cancer and other diseases.

Due to its broad-based applicability to detect compounds with a wide range of masses, along with its high sensitivity, mass spectrometry (MS) has been used extensively in a range of omics analyses and applications. In this listicle, we explore the use of MS-based data in a variety of clinical omics settings.

Download this listicle to find out more about:

Clinical omics and infectious diseases
Detection and monitoring of food allergens
Limitations of MS for clinical omics and comparison to other methods

Meet the Author

White letters "ML" on a navy background.

Mindy Levine, PhD

Professor

Professor Mindy Levine is currently researching supramolecular chemistry and chemical sensor development. Mindy was a faculty member at the University of Rhode Island from 2010-2019. She received her BA, MA, and PhD from Columbia University and completed an NIH-funded postdoctoral fellowship at MIT in the laboratory of Professor Timothy Swager. She has published more than 70 peer-reviewed publications to date, including 60 as an independent researcher and professor.